0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Haemophilus Parasuis Bivalent Vaccine Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-1U16967
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Haemophilus Parasuis Bivalent Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
BUY CHAPTERS

Global Haemophilus Parasuis Bivalent Vaccine Market Research Report 2025

Code: QYRE-Auto-1U16967
Report
May 2025
Pages:102
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Haemophilus Parasuis Bivalent Vaccine Market

The global market for Haemophilus Parasuis Bivalent Vaccine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Haemophilus parasuis disease, also known as Grazer"s disease, is an upper respiratory infectious disease of pigs caused by Haemophilus parasuis (HPS), mainly infecting piglets before and after weaning, clinically manifested as multiple fibrosis Serositis, arthritis and meningitis. The inactivated vaccine against Haemophilus parasuis can effectively prevent Haemophilus parasuis and reduce the mortality rate of Haemophilus parasuis infection.
North American market for Haemophilus Parasuis Bivalent Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Haemophilus Parasuis Bivalent Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Haemophilus Parasuis Bivalent Vaccine include Zoetis, Boehringer-Ingelheim, Eurovet, Hipra, Nisseiken, Merck Animal Health, SPAH, Pulike Biological Engineering, China Animal Husbandry Industry, Wuhan Keqian Biology, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Haemophilus Parasuis Bivalent Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Haemophilus Parasuis Bivalent Vaccine.
The Haemophilus Parasuis Bivalent Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Haemophilus Parasuis Bivalent Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Haemophilus Parasuis Bivalent Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Haemophilus Parasuis Bivalent Vaccine Market Report

Report Metric Details
Report Name Haemophilus Parasuis Bivalent Vaccine Market
Segment by Type
  • Bivalent Inactivated Vaccine
  • Trivalent Inactivated Vaccine
  • Quadrivalent Inactivated Vaccine
Segment by Application
  • Piglets
  • Adults Pigs
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Zoetis, Boehringer-Ingelheim, Eurovet, Hipra, Nisseiken, Merck Animal Health, SPAH, Pulike Biological Engineering, China Animal Husbandry Industry, Wuhan Keqian Biology, Wo Hua Biotech, Zhejiang Ceva Ebvac Biotech, Luoyang Huizhong Biotech, Beijing Centrebio Biology, Shandong Huahong Bioengineering, Ringpu
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Haemophilus Parasuis Bivalent Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Haemophilus Parasuis Bivalent Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Haemophilus Parasuis Bivalent Vaccine Market report?

Ans: The main players in the Haemophilus Parasuis Bivalent Vaccine Market are Zoetis, Boehringer-Ingelheim, Eurovet, Hipra, Nisseiken, Merck Animal Health, SPAH, Pulike Biological Engineering, China Animal Husbandry Industry, Wuhan Keqian Biology, Wo Hua Biotech, Zhejiang Ceva Ebvac Biotech, Luoyang Huizhong Biotech, Beijing Centrebio Biology, Shandong Huahong Bioengineering, Ringpu

What are the Application segmentation covered in the Haemophilus Parasuis Bivalent Vaccine Market report?

Ans: The Applications covered in the Haemophilus Parasuis Bivalent Vaccine Market report are Piglets, Adults Pigs

What are the Type segmentation covered in the Haemophilus Parasuis Bivalent Vaccine Market report?

Ans: The Types covered in the Haemophilus Parasuis Bivalent Vaccine Market report are Bivalent Inactivated Vaccine, Trivalent Inactivated Vaccine, Quadrivalent Inactivated Vaccine

1 Haemophilus Parasuis Bivalent Vaccine Market Overview
1.1 Product Definition
1.2 Haemophilus Parasuis Bivalent Vaccine by Type
1.2.1 Global Haemophilus Parasuis Bivalent Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Bivalent Inactivated Vaccine
1.2.3 Trivalent Inactivated Vaccine
1.2.4 Quadrivalent Inactivated Vaccine
1.3 Haemophilus Parasuis Bivalent Vaccine by Application
1.3.1 Global Haemophilus Parasuis Bivalent Vaccine Market Value by Application (2024 VS 2031)
1.3.2 Piglets
1.3.3 Adults Pigs
1.4 Global Haemophilus Parasuis Bivalent Vaccine Market Size Estimates and Forecasts
1.4.1 Global Haemophilus Parasuis Bivalent Vaccine Revenue 2020-2031
1.4.2 Global Haemophilus Parasuis Bivalent Vaccine Sales 2020-2031
1.4.3 Global Haemophilus Parasuis Bivalent Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Haemophilus Parasuis Bivalent Vaccine Market Competition by Manufacturers
2.1 Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Haemophilus Parasuis Bivalent Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Haemophilus Parasuis Bivalent Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Haemophilus Parasuis Bivalent Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Haemophilus Parasuis Bivalent Vaccine, Product Type & Application
2.7 Global Key Manufacturers of Haemophilus Parasuis Bivalent Vaccine, Date of Enter into This Industry
2.8 Global Haemophilus Parasuis Bivalent Vaccine Market Competitive Situation and Trends
2.8.1 Global Haemophilus Parasuis Bivalent Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Haemophilus Parasuis Bivalent Vaccine Players Market Share by Revenue
2.8.3 Global Haemophilus Parasuis Bivalent Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Haemophilus Parasuis Bivalent Vaccine Market Scenario by Region
3.1 Global Haemophilus Parasuis Bivalent Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Haemophilus Parasuis Bivalent Vaccine Sales by Region: 2020-2031
3.2.1 Global Haemophilus Parasuis Bivalent Vaccine Sales by Region: 2020-2025
3.2.2 Global Haemophilus Parasuis Bivalent Vaccine Sales by Region: 2026-2031
3.3 Global Haemophilus Parasuis Bivalent Vaccine Revenue by Region: 2020-2031
3.3.1 Global Haemophilus Parasuis Bivalent Vaccine Revenue by Region: 2020-2025
3.3.2 Global Haemophilus Parasuis Bivalent Vaccine Revenue by Region: 2026-2031
3.4 North America Haemophilus Parasuis Bivalent Vaccine Market Facts & Figures by Country
3.4.1 North America Haemophilus Parasuis Bivalent Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Haemophilus Parasuis Bivalent Vaccine Sales by Country (2020-2031)
3.4.3 North America Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Haemophilus Parasuis Bivalent Vaccine Market Facts & Figures by Country
3.5.1 Europe Haemophilus Parasuis Bivalent Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Haemophilus Parasuis Bivalent Vaccine Sales by Country (2020-2031)
3.5.3 Europe Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Haemophilus Parasuis Bivalent Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Haemophilus Parasuis Bivalent Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Haemophilus Parasuis Bivalent Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific Haemophilus Parasuis Bivalent Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Haemophilus Parasuis Bivalent Vaccine Market Facts & Figures by Country
3.7.1 Latin America Haemophilus Parasuis Bivalent Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Haemophilus Parasuis Bivalent Vaccine Sales by Country (2020-2031)
3.7.3 Latin America Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Haemophilus Parasuis Bivalent Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Haemophilus Parasuis Bivalent Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Haemophilus Parasuis Bivalent Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Haemophilus Parasuis Bivalent Vaccine Sales by Type (2020-2031)
4.1.1 Global Haemophilus Parasuis Bivalent Vaccine Sales by Type (2020-2025)
4.1.2 Global Haemophilus Parasuis Bivalent Vaccine Sales by Type (2026-2031)
4.1.3 Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Type (2020-2031)
4.2 Global Haemophilus Parasuis Bivalent Vaccine Revenue by Type (2020-2031)
4.2.1 Global Haemophilus Parasuis Bivalent Vaccine Revenue by Type (2020-2025)
4.2.2 Global Haemophilus Parasuis Bivalent Vaccine Revenue by Type (2026-2031)
4.2.3 Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global Haemophilus Parasuis Bivalent Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Haemophilus Parasuis Bivalent Vaccine Sales by Application (2020-2031)
5.1.1 Global Haemophilus Parasuis Bivalent Vaccine Sales by Application (2020-2025)
5.1.2 Global Haemophilus Parasuis Bivalent Vaccine Sales by Application (2026-2031)
5.1.3 Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Application (2020-2031)
5.2 Global Haemophilus Parasuis Bivalent Vaccine Revenue by Application (2020-2031)
5.2.1 Global Haemophilus Parasuis Bivalent Vaccine Revenue by Application (2020-2025)
5.2.2 Global Haemophilus Parasuis Bivalent Vaccine Revenue by Application (2026-2031)
5.2.3 Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global Haemophilus Parasuis Bivalent Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Zoetis
6.1.1 Zoetis Company Information
6.1.2 Zoetis Description and Business Overview
6.1.3 Zoetis Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Zoetis Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.1.5 Zoetis Recent Developments/Updates
6.2 Boehringer-Ingelheim
6.2.1 Boehringer-Ingelheim Company Information
6.2.2 Boehringer-Ingelheim Description and Business Overview
6.2.3 Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.2.5 Boehringer-Ingelheim Recent Developments/Updates
6.3 Eurovet
6.3.1 Eurovet Company Information
6.3.2 Eurovet Description and Business Overview
6.3.3 Eurovet Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Eurovet Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.3.5 Eurovet Recent Developments/Updates
6.4 Hipra
6.4.1 Hipra Company Information
6.4.2 Hipra Description and Business Overview
6.4.3 Hipra Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Hipra Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.4.5 Hipra Recent Developments/Updates
6.5 Nisseiken
6.5.1 Nisseiken Company Information
6.5.2 Nisseiken Description and Business Overview
6.5.3 Nisseiken Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Nisseiken Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.5.5 Nisseiken Recent Developments/Updates
6.6 Merck Animal Health
6.6.1 Merck Animal Health Company Information
6.6.2 Merck Animal Health Description and Business Overview
6.6.3 Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.6.5 Merck Animal Health Recent Developments/Updates
6.7 SPAH
6.7.1 SPAH Company Information
6.7.2 SPAH Description and Business Overview
6.7.3 SPAH Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 SPAH Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.7.5 SPAH Recent Developments/Updates
6.8 Pulike Biological Engineering
6.8.1 Pulike Biological Engineering Company Information
6.8.2 Pulike Biological Engineering Description and Business Overview
6.8.3 Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.8.5 Pulike Biological Engineering Recent Developments/Updates
6.9 China Animal Husbandry Industry
6.9.1 China Animal Husbandry Industry Company Information
6.9.2 China Animal Husbandry Industry Description and Business Overview
6.9.3 China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.9.5 China Animal Husbandry Industry Recent Developments/Updates
6.10 Wuhan Keqian Biology
6.10.1 Wuhan Keqian Biology Company Information
6.10.2 Wuhan Keqian Biology Description and Business Overview
6.10.3 Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.10.5 Wuhan Keqian Biology Recent Developments/Updates
6.11 Wo Hua Biotech
6.11.1 Wo Hua Biotech Company Information
6.11.2 Wo Hua Biotech Description and Business Overview
6.11.3 Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.11.5 Wo Hua Biotech Recent Developments/Updates
6.12 Zhejiang Ceva Ebvac Biotech
6.12.1 Zhejiang Ceva Ebvac Biotech Company Information
6.12.2 Zhejiang Ceva Ebvac Biotech Description and Business Overview
6.12.3 Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.12.5 Zhejiang Ceva Ebvac Biotech Recent Developments/Updates
6.13 Luoyang Huizhong Biotech
6.13.1 Luoyang Huizhong Biotech Company Information
6.13.2 Luoyang Huizhong Biotech Description and Business Overview
6.13.3 Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.13.5 Luoyang Huizhong Biotech Recent Developments/Updates
6.14 Beijing Centrebio Biology
6.14.1 Beijing Centrebio Biology Company Information
6.14.2 Beijing Centrebio Biology Description and Business Overview
6.14.3 Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.14.5 Beijing Centrebio Biology Recent Developments/Updates
6.15 Shandong Huahong Bioengineering
6.15.1 Shandong Huahong Bioengineering Company Information
6.15.2 Shandong Huahong Bioengineering Description and Business Overview
6.15.3 Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.15.5 Shandong Huahong Bioengineering Recent Developments/Updates
6.16 Ringpu
6.16.1 Ringpu Company Information
6.16.2 Ringpu Description and Business Overview
6.16.3 Ringpu Haemophilus Parasuis Bivalent Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Ringpu Haemophilus Parasuis Bivalent Vaccine Product Portfolio
6.16.5 Ringpu Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Haemophilus Parasuis Bivalent Vaccine Industry Chain Analysis
7.2 Haemophilus Parasuis Bivalent Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Haemophilus Parasuis Bivalent Vaccine Production Mode & Process Analysis
7.4 Haemophilus Parasuis Bivalent Vaccine Sales and Marketing
7.4.1 Haemophilus Parasuis Bivalent Vaccine Sales Channels
7.4.2 Haemophilus Parasuis Bivalent Vaccine Distributors
7.5 Haemophilus Parasuis Bivalent Vaccine Customer Analysis
8 Haemophilus Parasuis Bivalent Vaccine Market Dynamics
8.1 Haemophilus Parasuis Bivalent Vaccine Industry Trends
8.2 Haemophilus Parasuis Bivalent Vaccine Market Drivers
8.3 Haemophilus Parasuis Bivalent Vaccine Market Challenges
8.4 Haemophilus Parasuis Bivalent Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Haemophilus Parasuis Bivalent Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Haemophilus Parasuis Bivalent Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Haemophilus Parasuis Bivalent Vaccine Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Haemophilus Parasuis Bivalent Vaccine Sales (K Doses) of Key Manufacturers (2020-2025)
 Table 5. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Haemophilus Parasuis Bivalent Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Haemophilus Parasuis Bivalent Vaccine Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Haemophilus Parasuis Bivalent Vaccine Average Price (US$/Dose) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Haemophilus Parasuis Bivalent Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Haemophilus Parasuis Bivalent Vaccine, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Haemophilus Parasuis Bivalent Vaccine, Product Type & Application
 Table 12. Global Key Manufacturers of Haemophilus Parasuis Bivalent Vaccine, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Haemophilus Parasuis Bivalent Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Haemophilus Parasuis Bivalent Vaccine as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Haemophilus Parasuis Bivalent Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Haemophilus Parasuis Bivalent Vaccine Sales by Region (2020-2025) & (K Doses)
 Table 18. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Region (2020-2025)
 Table 19. Global Haemophilus Parasuis Bivalent Vaccine Sales by Region (2026-2031) & (K Doses)
 Table 20. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Region (2026-2031)
 Table 21. Global Haemophilus Parasuis Bivalent Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Region (2020-2025)
 Table 23. Global Haemophilus Parasuis Bivalent Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Region (2026-2031)
 Table 25. North America Haemophilus Parasuis Bivalent Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Haemophilus Parasuis Bivalent Vaccine Sales by Country (2020-2025) & (K Doses)
 Table 27. North America Haemophilus Parasuis Bivalent Vaccine Sales by Country (2026-2031) & (K Doses)
 Table 28. North America Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Haemophilus Parasuis Bivalent Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Haemophilus Parasuis Bivalent Vaccine Sales by Country (2020-2025) & (K Doses)
 Table 32. Europe Haemophilus Parasuis Bivalent Vaccine Sales by Country (2026-2031) & (K Doses)
 Table 33. Europe Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Haemophilus Parasuis Bivalent Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Haemophilus Parasuis Bivalent Vaccine Sales by Region (2020-2025) & (K Doses)
 Table 37. Asia Pacific Haemophilus Parasuis Bivalent Vaccine Sales by Region (2026-2031) & (K Doses)
 Table 38. Asia Pacific Haemophilus Parasuis Bivalent Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Haemophilus Parasuis Bivalent Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Haemophilus Parasuis Bivalent Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Haemophilus Parasuis Bivalent Vaccine Sales by Country (2020-2025) & (K Doses)
 Table 42. Latin America Haemophilus Parasuis Bivalent Vaccine Sales by Country (2026-2031) & (K Doses)
 Table 43. Latin America Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Haemophilus Parasuis Bivalent Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Haemophilus Parasuis Bivalent Vaccine Sales by Country (2020-2025) & (K Doses)
 Table 47. Middle East and Africa Haemophilus Parasuis Bivalent Vaccine Sales by Country (2026-2031) & (K Doses)
 Table 48. Middle East and Africa Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Haemophilus Parasuis Bivalent Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Haemophilus Parasuis Bivalent Vaccine Sales (K Doses) by Type (2020-2025)
 Table 51. Global Haemophilus Parasuis Bivalent Vaccine Sales (K Doses) by Type (2026-2031)
 Table 52. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Type (2020-2025)
 Table 53. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Type (2026-2031)
 Table 54. Global Haemophilus Parasuis Bivalent Vaccine Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Haemophilus Parasuis Bivalent Vaccine Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Type (2020-2025)
 Table 57. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Type (2026-2031)
 Table 58. Global Haemophilus Parasuis Bivalent Vaccine Price (US$/Dose) by Type (2020-2025)
 Table 59. Global Haemophilus Parasuis Bivalent Vaccine Price (US$/Dose) by Type (2026-2031)
 Table 60. Global Haemophilus Parasuis Bivalent Vaccine Sales (K Doses) by Application (2020-2025)
 Table 61. Global Haemophilus Parasuis Bivalent Vaccine Sales (K Doses) by Application (2026-2031)
 Table 62. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Application (2020-2025)
 Table 63. Global Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Application (2026-2031)
 Table 64. Global Haemophilus Parasuis Bivalent Vaccine Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Haemophilus Parasuis Bivalent Vaccine Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Application (2020-2025)
 Table 67. Global Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Application (2026-2031)
 Table 68. Global Haemophilus Parasuis Bivalent Vaccine Price (US$/Dose) by Application (2020-2025)
 Table 69. Global Haemophilus Parasuis Bivalent Vaccine Price (US$/Dose) by Application (2026-2031)
 Table 70. Zoetis Company Information
 Table 71. Zoetis Description and Business Overview
 Table 72. Zoetis Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 73. Zoetis Haemophilus Parasuis Bivalent Vaccine Product
 Table 74. Zoetis Recent Developments/Updates
 Table 75. Boehringer-Ingelheim Company Information
 Table 76. Boehringer-Ingelheim Description and Business Overview
 Table 77. Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 78. Boehringer-Ingelheim Haemophilus Parasuis Bivalent Vaccine Product
 Table 79. Boehringer-Ingelheim Recent Developments/Updates
 Table 80. Eurovet Company Information
 Table 81. Eurovet Description and Business Overview
 Table 82. Eurovet Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 83. Eurovet Haemophilus Parasuis Bivalent Vaccine Product
 Table 84. Eurovet Recent Developments/Updates
 Table 85. Hipra Company Information
 Table 86. Hipra Description and Business Overview
 Table 87. Hipra Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 88. Hipra Haemophilus Parasuis Bivalent Vaccine Product
 Table 89. Hipra Recent Developments/Updates
 Table 90. Nisseiken Company Information
 Table 91. Nisseiken Description and Business Overview
 Table 92. Nisseiken Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 93. Nisseiken Haemophilus Parasuis Bivalent Vaccine Product
 Table 94. Nisseiken Recent Developments/Updates
 Table 95. Merck Animal Health Company Information
 Table 96. Merck Animal Health Description and Business Overview
 Table 97. Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 98. Merck Animal Health Haemophilus Parasuis Bivalent Vaccine Product
 Table 99. Merck Animal Health Recent Developments/Updates
 Table 100. SPAH Company Information
 Table 101. SPAH Description and Business Overview
 Table 102. SPAH Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 103. SPAH Haemophilus Parasuis Bivalent Vaccine Product
 Table 104. SPAH Recent Developments/Updates
 Table 105. Pulike Biological Engineering Company Information
 Table 106. Pulike Biological Engineering Description and Business Overview
 Table 107. Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 108. Pulike Biological Engineering Haemophilus Parasuis Bivalent Vaccine Product
 Table 109. Pulike Biological Engineering Recent Developments/Updates
 Table 110. China Animal Husbandry Industry Company Information
 Table 111. China Animal Husbandry Industry Description and Business Overview
 Table 112. China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 113. China Animal Husbandry Industry Haemophilus Parasuis Bivalent Vaccine Product
 Table 114. China Animal Husbandry Industry Recent Developments/Updates
 Table 115. Wuhan Keqian Biology Company Information
 Table 116. Wuhan Keqian Biology Description and Business Overview
 Table 117. Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 118. Wuhan Keqian Biology Haemophilus Parasuis Bivalent Vaccine Product
 Table 119. Wuhan Keqian Biology Recent Developments/Updates
 Table 120. Wo Hua Biotech Company Information
 Table 121. Wo Hua Biotech Description and Business Overview
 Table 122. Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 123. Wo Hua Biotech Haemophilus Parasuis Bivalent Vaccine Product
 Table 124. Wo Hua Biotech Recent Developments/Updates
 Table 125. Zhejiang Ceva Ebvac Biotech Company Information
 Table 126. Zhejiang Ceva Ebvac Biotech Description and Business Overview
 Table 127. Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 128. Zhejiang Ceva Ebvac Biotech Haemophilus Parasuis Bivalent Vaccine Product
 Table 129. Zhejiang Ceva Ebvac Biotech Recent Developments/Updates
 Table 130. Luoyang Huizhong Biotech Company Information
 Table 131. Luoyang Huizhong Biotech Description and Business Overview
 Table 132. Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 133. Luoyang Huizhong Biotech Haemophilus Parasuis Bivalent Vaccine Product
 Table 134. Luoyang Huizhong Biotech Recent Developments/Updates
 Table 135. Beijing Centrebio Biology Company Information
 Table 136. Beijing Centrebio Biology Description and Business Overview
 Table 137. Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 138. Beijing Centrebio Biology Haemophilus Parasuis Bivalent Vaccine Product
 Table 139. Beijing Centrebio Biology Recent Developments/Updates
 Table 140. Shandong Huahong Bioengineering Company Information
 Table 141. Shandong Huahong Bioengineering Description and Business Overview
 Table 142. Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 143. Shandong Huahong Bioengineering Haemophilus Parasuis Bivalent Vaccine Product
 Table 144. Shandong Huahong Bioengineering Recent Developments/Updates
 Table 145. Ringpu Company Information
 Table 146. Ringpu Description and Business Overview
 Table 147. Ringpu Haemophilus Parasuis Bivalent Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 148. Ringpu Haemophilus Parasuis Bivalent Vaccine Product
 Table 149. Ringpu Recent Developments/Updates
 Table 150. Key Raw Materials Lists
 Table 151. Raw Materials Key Suppliers Lists
 Table 152. Haemophilus Parasuis Bivalent Vaccine Distributors List
 Table 153. Haemophilus Parasuis Bivalent Vaccine Customers List
 Table 154. Haemophilus Parasuis Bivalent Vaccine Market Trends
 Table 155. Haemophilus Parasuis Bivalent Vaccine Market Drivers
 Table 156. Haemophilus Parasuis Bivalent Vaccine Market Challenges
 Table 157. Haemophilus Parasuis Bivalent Vaccine Market Restraints
 Table 158. Research Programs/Design for This Report
 Table 159. Key Data Information from Secondary Sources
 Table 160. Key Data Information from Primary Sources
 Table 161. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Haemophilus Parasuis Bivalent Vaccine
 Figure 2. Global Haemophilus Parasuis Bivalent Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Haemophilus Parasuis Bivalent Vaccine Market Share by Type: 2024 & 2031
 Figure 4. Bivalent Inactivated Vaccine Product Picture
 Figure 5. Trivalent Inactivated Vaccine Product Picture
 Figure 6. Quadrivalent Inactivated Vaccine Product Picture
 Figure 7. Global Haemophilus Parasuis Bivalent Vaccine Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Haemophilus Parasuis Bivalent Vaccine Market Share by Application: 2024 & 2031
 Figure 9. Piglets
 Figure 10. Adults Pigs
 Figure 11. Global Haemophilus Parasuis Bivalent Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Haemophilus Parasuis Bivalent Vaccine Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Haemophilus Parasuis Bivalent Vaccine Sales (2020-2031) & (K Doses)
 Figure 14. Global Haemophilus Parasuis Bivalent Vaccine Average Price (US$/Dose) & (2020-2031)
 Figure 15. Haemophilus Parasuis Bivalent Vaccine Report Years Considered
 Figure 16. Haemophilus Parasuis Bivalent Vaccine Sales Share by Manufacturers in 2024
 Figure 17. Global Haemophilus Parasuis Bivalent Vaccine Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Haemophilus Parasuis Bivalent Vaccine Players: Market Share by Revenue in Haemophilus Parasuis Bivalent Vaccine in 2024
 Figure 19. Haemophilus Parasuis Bivalent Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Haemophilus Parasuis Bivalent Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Country (2020-2031)
 Figure 22. North America Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Country (2020-2031)
 Figure 23. United States Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Country (2020-2031)
 Figure 26. Europe Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Region (2020-2031)
 Figure 34. China Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Southeast Asia Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Latin America Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Country (2020-2031)
 Figure 42. Latin America Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Country (2020-2031)
 Figure 43. Mexico Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Brazil Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Argentina Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Middle East and Africa Haemophilus Parasuis Bivalent Vaccine Sales Market Share by Country (2020-2031)
 Figure 47. Middle East and Africa Haemophilus Parasuis Bivalent Vaccine Revenue Market Share by Country (2020-2031)
 Figure 48. Turkey Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. UAE Haemophilus Parasuis Bivalent Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Global Sales Market Share of Haemophilus Parasuis Bivalent Vaccine by Type (2020-2031)
 Figure 52. Global Revenue Market Share of Haemophilus Parasuis Bivalent Vaccine by Type (2020-2031)
 Figure 53. Global Haemophilus Parasuis Bivalent Vaccine Price (US$/Dose) by Type (2020-2031)
 Figure 54. Global Sales Market Share of Haemophilus Parasuis Bivalent Vaccine by Application (2020-2031)
 Figure 55. Global Revenue Market Share of Haemophilus Parasuis Bivalent Vaccine by Application (2020-2031)
 Figure 56. Global Haemophilus Parasuis Bivalent Vaccine Price (US$/Dose) by Application (2020-2031)
 Figure 57. Haemophilus Parasuis Bivalent Vaccine Value Chain
 Figure 58. Channels of Distribution (Direct Vs Distribution)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS